Program
FHND6091
A development code.
In Sino Biopharmaceutical's pipeline, 蛋白酶体抑制剂
. Its studies are mostly in Multiple Myeloma, led by Sino Biopharmaceutical.
Furthest: phase 1, since Feb 17, 20221 company-led study, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 11 open or running | phase 1since Feb 17, 2022 | Feb 17, 2022 | none ahead |
- Named in Sino Biopharmaceutical’s own pipeline as
FHND6091
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 17, 2022First study: phase 1 study in Multiple MyelomaFirst studyNCT05271682 · 40 planned · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05271682Multiple Myeloma · China | 1 | Recruiting | Dec 31, 2023 | 40 |
How it is read
Names in the registry
- “FHND6091”, 1 entry
Codes read as this program: FHND6091.
Conditions, from the studies’ own filings
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.